• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

他汀类药物对肺动脉高压的治疗有益吗?

Are statins beneficial for the treatment of pulmonary hypertension?

作者信息

Wang Lei, Yang Ting, Wang Chen

机构信息

Department of Pulmonary and Critical Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

Department of Respiratory Medicine, Capital Medical University, Beijing 100069, China.

出版信息

Chronic Dis Transl Med. 2017 Dec 11;3(4):213-220. doi: 10.1016/j.cdtm.2017.10.001. eCollection 2017 Dec.

DOI:10.1016/j.cdtm.2017.10.001
PMID:29354804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5747501/
Abstract

Pulmonary hypertension (PH) is a condition characterized by vasoconstriction and vascular remodeling with a poor prognosis. The current medical treatments available are supportive care therapy and pulmonary vascular-targeted therapy. Targeted treatments for PH include prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors; however, these treatments cannot reverse pulmonary vascular remodeling. Recently, many novel treatment options involving drugs such as statins have been emerging. In this review, we attempt to summarize the current knowledge of the role of statins in PH treatment and their potential clinical effects. Many basic researches have proved that statins can be helpful for the treatment of PH both and in experimental models. The main mechanisms underlying the effects of statins are restoration of endothelial function, attenuation of pulmonary vascular remodeling, regulation of gene expression, regulation of intracellular signaling processes involved in PH, anti-inflammatory responses, and synergy with other targeted drugs. Nevertheless, clinical researches, especially randomized controlled trials for PH are rare. The current clinical researches show contrasting results on the clinical effects of statins in patients with PH. Carefully designed randomized, controlled trials are needed to test the safety and efficacy of statins for PH treatment.

摘要

肺动脉高压(PH)是一种以血管收缩和血管重塑为特征且预后不良的疾病。目前可用的医学治疗方法是支持性护理疗法和肺血管靶向疗法。PH的靶向治疗包括前列环素类似物、内皮素受体拮抗剂和5型磷酸二酯酶抑制剂;然而,这些治疗方法无法逆转肺血管重塑。最近,许多涉及他汀类药物等药物的新型治疗选择不断涌现。在本综述中,我们试图总结目前关于他汀类药物在PH治疗中的作用及其潜在临床效果的知识。许多基础研究已证明,他汀类药物在临床和实验模型中都有助于治疗PH。他汀类药物发挥作用的主要机制包括恢复内皮功能、减轻肺血管重塑、调节基因表达、调节参与PH的细胞内信号传导过程、抗炎反应以及与其他靶向药物协同作用。尽管如此,临床研究,尤其是针对PH的随机对照试验很少。目前的临床研究对他汀类药物在PH患者中的临床效果显示出相互矛盾的结果。需要精心设计的随机对照试验来测试他汀类药物治疗PH的安全性和有效性。

相似文献

1
Are statins beneficial for the treatment of pulmonary hypertension?他汀类药物对肺动脉高压的治疗有益吗?
Chronic Dis Transl Med. 2017 Dec 11;3(4):213-220. doi: 10.1016/j.cdtm.2017.10.001. eCollection 2017 Dec.
2
Medical therapies for pulmonary arterial hypertension.肺动脉高压的医学治疗方法。
Heart Fail Rev. 2016 May;21(3):273-83. doi: 10.1007/s10741-016-9527-x.
3
Pulmonary hypertension in COPD: pathophysiology and therapeutic targets.COPD 相关肺动脉高压:病理生理学和治疗靶点。
Curr Drug Targets. 2011 Apr;12(4):501-13. doi: 10.2174/138945011794751483.
4
[Update in basic research in the therapy of pulmonary arterial hypertension].[肺动脉高压治疗的基础研究进展]
Dtsch Med Wochenschr. 2008 Oct;133 Suppl 6:S170-2. doi: 10.1055/s-0028-1091230. Epub 2008 Sep 23.
5
Reactive oxygen species as therapeutic targets in pulmonary hypertension.活性氧作为肺动脉高压的治疗靶点。
Ther Adv Respir Dis. 2013 Jun;7(3):175-200. doi: 10.1177/1753465812472940. Epub 2013 Jan 17.
6
An evidence-based approach to the management of pulmonary arterial hypertension.一种基于证据的肺动脉高压管理方法。
Curr Opin Cardiol. 2006 Jul;21(4):385-92. doi: 10.1097/01.hco.0000231410.07426.9b.
7
Advances in the medical treatment of pulmonary hypertension.肺动脉高压的医学治疗进展。
Kidney Blood Press Res. 2005;28(5-6):311-24. doi: 10.1159/000090186. Epub 2006 Mar 7.
8
[Update: Preclinical developments for the treatment of pulmonary arterial hypertension].[更新:肺动脉高压治疗的临床前进展]
Dtsch Med Wochenschr. 2009 Aug;134 Suppl 5:S157-9. doi: 10.1055/s-0029-1225313. Epub 2009 Aug 28.
9
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].[5型磷酸二酯酶抑制剂治疗肺动脉高压]
Anadolu Kardiyol Derg. 2010 Sep;10 Suppl 2:16-8. doi: 10.5152/akd.2010.125.
10
Novel Strategies in the Treatment of Pulmonary Arterial Hypertension.肺动脉高压治疗的新策略
Curr Drug Targets. 2016;17(7):817-23. doi: 10.2174/1389450116666150722140424.

引用本文的文献

1
Monocrotaline-induced pulmonary arterial hypertension: the benefic effects of magnesium sulfate, Rosuvastatin and Sildenafil.野百合碱诱导的肺动脉高压:硫酸镁、瑞舒伐他汀和西地那非的有益作用。
Med Pharm Rep. 2024 Oct;97(4):528-539. doi: 10.15386/mpr-2804. Epub 2024 Oct 30.
2
Magnesium Sulfate, Rosuvastatin, Sildenafil and Their Combination in Chronic Hypoxia-Induced Pulmonary Hypertension in Male Rats.硫酸镁、瑞舒伐他汀、西地那非及其联合用药对雄性大鼠慢性低氧性肺动脉高压的影响
Life (Basel). 2024 Sep 20;14(9):1193. doi: 10.3390/life14091193.
3
The mitochondrial redistribution of ENOS is regulated by AKT1 and dimer status.ENOS 的线粒体重分布受 AKT1 和二聚体状态的调节。
Nitric Oxide. 2024 Nov 1;152:90-100. doi: 10.1016/j.niox.2024.09.009. Epub 2024 Sep 25.
4
Simvastatin restores pulmonary endothelial function in the setting of pulmonary over-circulation.辛伐他汀可恢复肺循环过度时的肺内皮功能。
Nitric Oxide. 2024 Jan 1;142:58-68. doi: 10.1016/j.niox.2023.11.007. Epub 2023 Dec 5.
5
NADPH oxidase family proteins: signaling dynamics to disease management.NADPH 氧化酶家族蛋白:信号动态与疾病管理。
Cell Mol Immunol. 2022 Jun;19(6):660-686. doi: 10.1038/s41423-022-00858-1. Epub 2022 May 18.
6
Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension.低密度脂蛋白受体、低密度脂蛋白受体相关蛋白与脂蛋白在肺动脉高压中的相互作用
JACC Basic Transl Sci. 2022 Feb 28;7(2):164-180. doi: 10.1016/j.jacbts.2021.09.011. eCollection 2022 Feb.
7
Antioxidant Therapy in Inflammatory Bowel Diseases.炎症性肠病中的抗氧化治疗
Antioxidants (Basel). 2021 Mar 9;10(3):412. doi: 10.3390/antiox10030412.
8
Anti-inflammatory Effects of Statins in Lung Vascular Pathology: From Basic Science to Clinical Trials.他汀类药物在肺血管病变中的抗炎作用:从基础科学到临床试验。
Adv Exp Med Biol. 2021;1303:33-56. doi: 10.1007/978-3-030-63046-1_3.
9
Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH.他汀类药物治疗可预防 HIV 相关肺动脉高压非人灵长类动物模型中肺动脉高压的发展。
Sci Rep. 2019 Dec 27;9(1):19832. doi: 10.1038/s41598-019-55301-9.
10
Pulmonary vascular dysfunction in metabolic syndrome.代谢综合征中的肺血管功能障碍。
J Physiol. 2019 Feb;597(4):1121-1141. doi: 10.1113/JP275856. Epub 2018 Sep 12.

本文引用的文献

1
Linking Vascular Remodeling and Inflammation in Pulmonary Arterial Hypertension: Is There a Common Root Cause?肺动脉高压中血管重塑与炎症的关联:是否存在共同的根本原因?
Am J Respir Cell Mol Biol. 2017 Jul;57(1):15-17. doi: 10.1165/rcmb.2017-0102ED.
2
Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study.他汀类药物治疗可改善重度肺动脉高压患者的生存率:一项倾向评分匹配研究。
Heart Vessels. 2017 Aug;32(8):969-976. doi: 10.1007/s00380-017-0957-8. Epub 2017 Mar 16.
3
Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins.药物发现与靶点解析中的技术进步及蛋白质组学应用:他汀类药物多效性效应的鉴定
Drug Discov Today. 2017 Jun;22(6):848-869. doi: 10.1016/j.drudis.2017.03.001. Epub 2017 Mar 8.
4
Statins ameliorate pulmonary hypertension secondary to left ventricular dysfunction through the Rho-kinase pathway and NADPH oxidase.他汀类药物通过Rho激酶途径和NADPH氧化酶改善继发于左心室功能障碍的肺动脉高压。
Pediatr Pulmonol. 2017 Apr;52(4):443-457. doi: 10.1002/ppul.23610. Epub 2016 Dec 28.
5
Efficacy and Safety of Statins for Pulmonary Hypertension: A Meta-Analysis of Randomised Controlled Trials.他汀类药物治疗肺动脉高压的疗效与安全性:一项随机对照试验的荟萃分析
Heart Lung Circ. 2017 May;26(5):425-432. doi: 10.1016/j.hlc.2016.08.005. Epub 2016 Sep 15.
6
A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension.一项前瞻性随机研究:瑞舒伐他汀对慢性阻塞性肺疾病合并肺动脉高压患者疗效的评估。
Indian J Pharmacol. 2016 Sep-Oct;48(5):503-508. doi: 10.4103/0253-7613.190721.
7
Simvastatin prevents and reverses chronic pulmonary hypertension in newborn rats via pleiotropic inhibition of RhoA signaling.辛伐他汀通过多效性抑制RhoA信号通路预防和逆转新生大鼠慢性肺动脉高压。
Am J Physiol Lung Cell Mol Physiol. 2016 Nov 1;311(5):L985-L999. doi: 10.1152/ajplung.00345.2016. Epub 2016 Sep 30.
8
A systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension.一项关于使用他汀类药物治疗肺动脉高压的试验的系统评价和荟萃分析。
Pulm Circ. 2016 Sep;6(3):295-301. doi: 10.1086/687304.
9
Rosuvastatin alleviates the development of monocrotaline-induced pulmonary hypertension in rats.瑞舒伐他汀可减轻大鼠由野百合碱诱导的肺动脉高压的发展。
J Biol Regul Homeost Agents. 2016 Jul-Sep;30(3):755-759.
10
Rosuvastatin intensifies the beneficial effects of rho-kinase inhibitor in reversal of monocrotaline-induced pulmonary hypertension.瑞舒伐他汀增强了Rho激酶抑制剂在逆转野百合碱诱导的肺动脉高压中的有益作用。
Arch Med Sci. 2016 Aug 1;12(4):898-905. doi: 10.5114/aoms.2015.49740. Epub 2015 May 22.